Evidence map›Paper›PMID 25889591›Full record

ArticleStem cell research & therapy2015

Nuclear reprogramming with a non-integrating human RNA virus.

Christopher B Driscoll, Jason M Tonne, Moustafa El Khatib, Roberto Cattaneo, Yasuhiro Ikeda, Patricia Devaux

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing.Molecular therapy. Methods & clinical development · 2024
    Article
  3. Review
  4. miRNA-mediated control of exogenousMolecular therapy. Methods & clinical development · 2022
    Article
  5. Live Attenuated Measles Virus Vaccine ExpressingMolecular therapy oncolytics · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Viral and Synthetic RNA Vector Technologies and Applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christopher B DriscollDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. driscoll.christopher@mayo.edu.
Jason M TonneDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. tonne.jason@mayo.edu.
Moustafa El KhatibDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. elkhatib.moustafa@mayo.edu.
Roberto CattaneoDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. cattaneo.roberto@mayo.edu.
Yasuhiro IkedaDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. ikeda.yasuhiro@mayo.edu.
Patricia DevauxDepartment of Molecular Medicine, and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. devaux.patricia@mayo.edu.
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Measles vectors for genomic modification-free induced pluripotent stem cellsR21AI105233 · NIAID · MAYO CLINIC ROCHESTER · PI DEVAUX, PATRICIA · 2013 to 2014
$437k
NCI NIH HHS 5P30 CA15083-36NCI NIH HHS P30 CA015083NIAID NIH HHS R21 AI105233NIAID NIH HHS R21AI105233
6 · The paper itself

Abstract

introductionAdvances in the field of stem cells have led to novel avenues for generating induced pluripotent stem cells (iPSCs) from differentiated somatic cells. iPSCs are typically obtained by the introduction of four factors--OCT4, SOX2, KLF4, and cMYC--via integrating vectors. Here, we report the feasibility of a novel reprogramming process based on vectors derived from the non-integrating vaccine strain of measles virus (MV).

methodsWe produced a one-cycle MV vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. This vector was further engineered to encode for OCT4 in an additional transcription unit.

resultsAfter verification of OCT4 expression, we assessed the ability of iPSC reprogramming. The reprogramming vector cocktail with the OCT4-expressing MV vector and SOX2-, KLF4-, and cMYC-expressing lentiviral vectors efficiently transduced human skin fibroblasts and formed iPSC colonies. Reverse transcription-polymerase chain reaction and immunostaining confirmed induction of endogenous pluripotency-associated marker genes, such as SSEA-4, TRA-1-60, and Nanog. Pluripotency of derived clones was confirmed by spontaneous differentiation into three germ layers, teratoma formation, and guided differentiation into beating cardiomyocytes.

conclusionsMV vectors can induce efficient nuclear reprogramming. Given the excellent safety record of MV vaccines and the translational capabilities recently developed to produce MV-based vectors now used for cancer clinical trials, our MV vector system provides an RNA-based, non-integrating gene transfer platform for nuclear reprogramming that is amenable for immediate clinical translation.

Indexed as

AnimalsAntigens, SurfaceBiomarkersCell LineCellular ReprogrammingChlorocebus aethiopsFibroblastsForeskinHEK293 CellsHomeodomain ProteinsHumansInduced Pluripotent Stem CellsKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeasles virusAntigens, SurfaceBiomarkersHomeodomain ProteinsKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Kruppel-Like Transcription FactorsMYC protein, humanNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProteoglycansProto-Oncogene Proteins c-mycSOX2 protein, humanSOXB1 Transcription Factorsstage-specific embryonic antigen-4Stage-Specific Embryonic AntigensTRA-1-60 antigen, human

Identifiers

PMID25889591
PMCPMC4415226
OpenAlexW2104613814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.